Advertisement

Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib

  • Prasanth Ganesan
  • Thanda Joshua
  • Shirley Sundersingh
  • Tenali Gnana Sagar
Correspondence
  • 42 Downloads

Keywords

Anaplastic large cell lymphoma ALK+ve Crizotinib ALK Targeted therapy 

Notes

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical Approval

This is a retrospective data analysis and no patient identifying information is being included in the manuscript. As per our Institution policy, we don’t require ethical approval for retrospective analysis.

References

  1. 1.
    Ferreri AJ, Govi S, Pileri SA, Savage KJ (2012) Anaplastic large cell lymphoma, ALK-positive. Crit Rev Oncol Hematol 83(2):293–302CrossRefPubMedGoogle Scholar
  2. 2.
    Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364(8):775–776CrossRefPubMedGoogle Scholar
  3. 3.
    Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J et al (2013) Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol 14(6):472–480CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lai R, Ingham RJ (2013) The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update. Ther Adv Hematol 4(2):119–131CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Redaelli S, Farina F, Stasia A, Ceccon M, Mologni L, Messa C et al (2013) High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. Blood 122:368Google Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2017

Authors and Affiliations

  1. 1.Department of Medical OncologyCancer Institute (WIA)ChennaiIndia
  2. 2.Department of PathologyCancer Institute (WIA)ChennaiIndia

Personalised recommendations